目前在胶质母细胞瘤中与 PD-1/PD-L1 轴相关的肿瘤浸润免疫细胞和治疗方案的进展。
Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
机构信息
Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Tianjin Huan Hu Hospital, Tianjin, 300350, China; Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, 300350, China.
Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, 300350, China.
出版信息
Crit Rev Oncol Hematol. 2020 Jul;151:102965. doi: 10.1016/j.critrevonc.2020.102965. Epub 2020 Apr 24.
Glioblastoma (GBM) is the most common malignant tumour in the brain, and current treatments are not curative and cannot control recurrence. This limitation indirectly places immunotherapy at the focus of translational GBM research. Many studies on the PD-1/PD-L1 axis in GBM are ongoing, and the immunosuppressive mechanism of PD-1/PD-L1 in GBM is different from that in other solid tumours. This review focuses on the effect of the PD-1/PD-L1 axis on infiltrating immune cells in the suppressive GBM immune microenvironment and summarizes the recent progress in PD-1/PD-L1 axis-related therapies reported in preclinical and clinical GBM studies, providing a reference for the systematic study of PD-1/PD-L1 axis-related anti-GBM immunity.
胶质母细胞瘤（GBM）是最常见的脑恶性肿瘤，目前的治疗方法无法治愈，也无法控制复发。这种局限性间接将免疫疗法置于 GBM 转化研究的焦点。目前正在进行许多关于 GBM 中 PD-1/PD-L1 轴的研究，并且 GBM 中 PD-1/PD-L1 的免疫抑制机制与其他实体瘤不同。本综述重点关注 PD-1/PD-L1 轴对抑制性 GBM 免疫微环境中浸润免疫细胞的影响，并总结了最近在 GBM 的临床前和临床研究中报道的 PD-1/PD-L1 轴相关治疗的进展，为 PD-1/PD-L1 轴相关抗 GBM 免疫的系统研究提供参考。
Zotero 插件